

# Kipp Weiskopf

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11405648/publications.pdf>

Version: 2024-02-01

33  
papers

5,898  
citations

257450

24  
h-index

434195

31  
g-index

33  
all docs

33  
docs citations

33  
times ranked

7737  
citing authors

#	ARTICLE	IF	CITATIONS
1	The CD47-signal regulatory protein alpha (SIRP $\alpha$ ) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6662-6667.	7.1	1,255
2	Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47. Science Translational Medicine, 2010, 2, 63ra94.	12.4	591
3	Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11103-11108.	7.1	518
4	Engineered SIRP $\alpha$ Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies. Science, 2013, 341, 88-91.	12.6	401
5	Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology, 2018, 19, 76-84.	14.5	370
6	CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. Journal of Clinical Investigation, 2016, 126, 2610-2620.	8.2	336
7	Cancer immunotherapy targeting the CD47/SIRP $\alpha$ axis. European Journal of Cancer, 2017, 76, 100-109.	2.8	280
8	Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6656-6661.	7.1	225
9	Macrophages are critical effectors of antibody therapies for cancer. MAbs, 2015, 7, 303-310.	5.2	223
10	Anti-SIRP $\alpha$ antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10578-E10585.	7.1	223
11	Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. Journal of Clinical Investigation, 2012, 122, 1066-1075.	8.2	202
12	CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood, 2011, 117, 2423-2432.	1.4	195
13	Targeting CD137 enhances the efficacy of cetuximab. Journal of Clinical Investigation, 2014, 124, 2668-2682.	8.2	154
14	Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps. Immunity, 2015, 42, 826-838.	14.3	147
15	Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Science Translational Medicine, 2016, 8, 351ra105.	12.4	140
16	A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs, 2015, 7, 946-956.	5.2	117
17	Velcro-Engineering of High Affinity CD47 Ectodomain as Signal Regulatory Protein $\alpha$ (SIRP $\alpha$ ) Antagonists That Enhance Antibody-dependent Cellular Phagocytosis. Journal of Biological Chemistry, 2015, 290, 12650-12663.	3.4	75
18	Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4464-4469.	7.1	70

#	ARTICLE	IF	CITATIONS
19	Myeloid Cell Origins, Differentiation, and Clinical Implications. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	59
20	Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts. <i>Cell Reports</i> , 2016, 16, 1701-1716.	6.4	56
21	Delivery of monocyte lineage cells in a biomimetic scaffold enhances tissue repair. <i>JCI Insight</i> , 2017, 2, .	5.0	55
22	Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20. <i>Cancer Immunology Research</i> , 2016, 4, 1072-1087.	3.4	46
23	Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3501-3506.	7.1	44
24	SIRP $\beta$ -Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells. <i>Clinical Cancer Research</i> , 2016, 22, 5109-5119.	7.0	37
25	Targeting lymphoma with precision using semisynthetic anti-idiotypic peptibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5376-5381.	7.1	22
26	Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRP $\beta$ variants. <i>Oncolmmunology</i> , 2013, 2, e25773.	4.6	13
27	Salmonella Infection Enhances Erythropoietin Production by the Kidney and Liver, Which Correlates with Elevated Bacterial Burdens. <i>Infection and Immunity</i> , 2016, 84, 2833-2841.	2.2	13
28	Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade. <i>Melanoma Research</i> , 2020, 30, 147-158.	1.2	12
29	Flipping the script on macrophages in leiomyosarcoma. <i>Oncolmmunology</i> , 2012, 1, 1202-1204.	4.6	8
30	Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors. <i>Oncolmmunology</i> , 2013, 2, e24452.	4.6	5
31	CD47-blocking therapies stimulate macrophage cytokine secretion and are effective in a model of peritoneal carcinomatosis. , 2015, 3, .		4
32	Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction. <i>Journal of Oncology Practice</i> , 2016, 12, 763-764.	2.5	1
33	Myeloid Cell Origins, Differentiation, and Clinical Implications. , 2017, , 857-875.		1